ClinicalTrials.gg
RecruitingNCT07055594NbTAST-01Updated Nov 6, 2025

A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors

A Phase 1/2 interventional study of SOA101 in Solid Tumors, sponsored by Shine-On Biomedical Co., Ltd.. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-06.

Sponsored by Shine-On Biomedical Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The investigational drug, SOA101, is a nanobody-based trispecific antibody T cell engager targeting PD-L1/HLA-G/CD3. This is a Phase I/IIa study including dose-escalation, dose optimization and dose expansion parts to exam safety, tolerability, pharmacokinetics, immunogenecity and efficacy of SOA101 on advanced or metastatic solid tumor treatment.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Shine-On Biomedical Co., Ltd. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged ≥ 18 years old.
  2. Subjects with locally advanced, or solid tumors confirmed histologically or cytologically as one of the following cancer types for whom no suitable alternative standard-of-care therapy exists:

    1. Non-small cell lung cancer (NSCLC);
    2. Ovarian cancer (OC);
    3. Head and neck carcinoma (H\&N);
    4. Breast cancer (BC);
    5. Colorectal cancer (CRC).
  3. confirmed combined positive score (CPS) with ≥ 1% expression of .
  4. At least one
  5. Adequate organ function
  6. Female subject must either not be of or a negative pregnancy test
  7. Non-vasectomized male subjects must practice highly effective

Exclusion criteria

Exclusion Criteria:

  1. Active bacterial, fungal, viral OR atypical infection requiring systemic medication.
  2. Received any drug within 4 weeks before screening.
  3. Confirmed active (without controlled disease on HAART), , or infection.
  4. Symptomatic, unstable central nervous system OR
  5. Have received organ or tissue transplantation or allogeneic cell therapies.
  6. Non-adequate cardiac function
  7. Known to any therapy or anti-CD3 therapy.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    SOA101

    Drug: SOA101

Interventions

  • DrugSOA101

    Participants will receive SOA101. The RP2D will be determined based on the results of the Phase I study. During the dose expansion phase, participants will receive SOA101 at the RP2D regimen.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of SOA101 for Phase I

    Time frame: from start until 3 months after the last dosing

  2. Objective Response Rate (ORR) of SOA101 for Phase IIa

    Time frame: from start until 3 months after the last dosing

Secondary outcomes

  1. Area Under the Curve of SOA101 (AUC)

    Pharmacokinetics (PK) parameters

    Time frame: Up to end of study visit (90 days after the last dose)

  2. Maximum observed plasma concentration of SOA101 (Cmax)

    Pharmacokinetics (PK) parameters

    Time frame: Up to end of study visit (90 days after the last dose)

  3. Half-life of SOA101 (T1/2)

    Pharmacokinetics (PK) parameters

    Time frame: Up to end of study visit (90 days after the last dose)

  4. Overall Response Rate (ORR)

    Evaluation of anti-tumor activity of SOA101

    Time frame: Up to end of study visit (90 days after the last dose)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lin YC, Chen MC, Huang SW, Chen Y, Ho JH, Lin FY, Tan XT, Chiang HC, Huang CC, Tu CY, Cho DY, Chiu SC. Targeting Dual Immune Checkpoints PD-L1 and HLA-G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer. Adv Sci (Weinh). 2024 Nov;11(41):e2309697. doi: 10.1002/advs.202309697. Epub 2024 Sep 5. PubMed 39234811 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Feb 2028, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jul 9, 2025
StartActual
Jul 30, 2025
Primary completionEst.
Feb 2028
CompletionEst.
Dec 2028
Last update
Nov 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07055594
Lead sponsor
Shine-On Biomedical Co., Ltd.
Responsible party
Sponsor
First posted
Jul 9, 2025
Start date
Jul 30, 2025
Primary completion
Feb 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 6, 2025

Study contacts

Jennifer Ho
Contact
rd005@shineon-bio.com
+886423272888
Oscar Yang
Contact
rd009@shineon-bio.com

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion